Equally important will be the search for predictive biomarkers to identify patients most likely to benefit; lessons from NSCLC, where HER2 mutations and c-MET overexpression have defined ADC activity, illustrate the potential for biomarker-driven selection in lung cancer and eventually also in SCLC. This evidence concerns the gene MET and lung cancer.